Xeris Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Xeris Pharmaceuticals, Inc. - overview
Established
2005
Location
Chicago, IL, US
Primary Industry
Pharmaceuticals
About
Xeris Pharmaceuticals, Inc. is a U. S. -based biopharmaceutical firm focused on innovative drug delivery solutions, particularly in endocrinology and neurology, enhancing patient accessibility and compliance with medication regimens.
Founded in 2005, Xeris Pharmaceuticals, Inc. operates from Chicago, US, specializing in developing drug delivery systems. The company raised USD 86 mn in an IPO in June 2018 and further secured USD 27 mn in a Private Placement in March 2021. The CEO, Paul Edick, has led the company in addressing critical health issues with innovative solutions.
Xeris Pharmaceuticals specializes in the development and commercialization of innovative drug delivery systems, particularly in the fields of endocrinology and neurology. The company's core product offerings include unique formulations that enable patients to administer medications conveniently and effectively, particularly using their proprietary technology that simplifies the delivery of complex biologics. Their flagship products address critical health issues, including diabetes management through a steady supply of insulin, and they aim to enhance patient compliance by reducing the burden of multiple daily injections. Xeris primarily serves healthcare providers, patients, and specialty pharmacies, with a focus on the U.
S. market, while also exploring opportunities in Europe and other international markets for expansion. In the most recent fiscal year 2020, Xeris Pharmaceuticals reported a revenue of USD 20. 15 mn and an EBITDA of USD -81.
02 mn. Revenue is generated through direct sales to healthcare providers and partnerships with specialty pharmacies, reflecting the innovative delivery technology and significant health outcomes they provide. Xeris Pharmaceuticals plans to leverage the USD 27 mn raised in March 2021 for working capital and other corporate purposes, focusing on upcoming product launches and potential new markets. The company aims to expand its reach into European markets and enhance its product offerings that address chronic health conditions, capitalizing on its proprietary drug delivery technologies.
Current Investors
Palmetto Partners, Bay City Capital, Merieux Equity Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.xerispharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Xeris Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Xeris Pharmaceuticals, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.